Literature DB >> 18807040

[Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].

P Mainka1, S Kahlert, T Kirchner, D Mayr, J Diebold.   

Abstract

AIMS: The aim of the present study was to evaluate the prognostic impact of basal and myoepithelial phenotype in breast carcinomas (BBC and MBC) in the palliative situation.
METHODS: Paraffin-embedded material from 244 primary breast carcinomas of patients with subsequent metastatic disease was stained immunohistochemically for CK 5/6, CK14, smooth-muscle actin, p63, estrogen receptor and progesterone receptor. BBC was defined as positive for CK5/6 and/or CK14 and MBC as positive for SMA and/or p63. Clinical and pathological data were available for all patients and follow-up data for 96.3% (range 5 days-151 months).
RESULTS: Until the end of the follow-up period 90.2% of patients died and 6.1% are still alive. Of the tumours 28.7% could be classified as BBC and 8.2% as MBC. Kaplan Meier analysis revealed a trend for reduced survival after first diagnosis of metastasis (OASM) for BBC and MBC. Differences in survival were significant for BBC (log-rank =5.0; p=0.025), but not for MBC. CK5/6+ and CK14+ double positive tumours (n=18; 7.4%) were identified as a subgroup of BBC associated with reduced OASM (log-rank=8,6; p=0.003). This subgroup, but not BBC or MBC was an independent negative prognostic factor in a multivariate analysis including age, typing, tumour size, grading, axillary nodes, HR, Her2/neu, site of first metastasis and disease-free interval.
CONCLUSION: The association of BBC and MBC with reduced OASM in metastatic breast carcinomas is not independent from established prognostic factors. CK5/6+ CK14+ double positive tumours may be a subgroup of BBC with particularly unfavourable outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18807040     DOI: 10.1007/s00292-008-1032-0

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  25 in total

1.  Prognostic relevance of basal cytokeratin expression in operable breast cancer.

Authors:  Piotr Potemski; Renata Kusinska; Cezary Watala; Elzbieta Pluciennik; Andrzej K Bednarek; Radzislaw Kordek
Journal:  Oncology       Date:  2006-01-12       Impact factor: 2.935

Review 2.  Metastatic breast cancer.

Authors:  C H Cha; G D Kennedy; J E Niederhuber
Journal:  Surg Clin North Am       Date:  1999-10       Impact factor: 2.741

3.  Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.

Authors:  Mervi Laakso; Minna Tanner; Jonas Nilsson; Tom Wiklund; Björn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Bergh; Jorma Isola
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

4.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

Authors:  E A Rakha; T C Putti; D M Abd El-Rehim; C Paish; A R Green; D G Powe; A H Lee; J F Robertson; I O Ellis
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 6.  Survival after first recurrence of breast cancer. The Miami experience.

Authors:  C L Vogel; S Azevedo; S Hilsenbeck; D R East; J Ayub
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

Review 7.  The phenotypic spectrum of basal-like breast cancers: a critical appraisal.

Authors:  Oluwole Fadare; Fattaneh A Tavassoli
Journal:  Adv Anat Pathol       Date:  2007-09       Impact factor: 3.875

8.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

9.  Human breast cancer: survival from first metastasis. Breast Cancer Study Group.

Authors:  P G Koenders; L V Beex; P W Kloppenborg; A G Smals; T J Benraad
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?

Authors:  Brigitte Rack; Wolfgang Janni; Bernd Gerber; Barbara Strobl; Christian Schindlbeck; Elisabeth Klanner; Gerhard Rammel; Harald Sommer; Thomas Dimpfl; Klaus Friese
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.